---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-212020"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:47:19.457346+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Stoke reports Q1 net loss $50M; new 4-year OLE data supports zorevunersen disease-modifying potential

## Summary
- Net loss $50.0M ($0.79/share) vs prior-year net income $112.9M; revenue $6.2M down from $158.6M due to 2025 Biogen license revenue.
- Cash $411M funded into 2028; includes $80.7M from ATM sales of 2.6M shares in Q1.
- New 4-year OLE data: durable seizure reductions, statistically significant cognition/behavior gains at 1-4 years; generally well tolerated.
- Phase 3 EMPEROR enrollment (~150 pts) expected to complete June 2026, data readout mid-2027; NDA submission planned Q1 2027.
- First patient dosed in Phase 1 OSPREY (STK-002 for ADOA); SYNGAP1 candidate selection targeted in 2026.

## SEC filing metadata
- accession: 0001193125-26-212020
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/0001193125-26-212020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/stok-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-212020
- JSON: https://secwatch.observer/filing/0001193125-26-212020.json
- Plain text: https://secwatch.observer/filing/0001193125-26-212020.txt

## Source-grounded claims
- claim_id: 9df5a5d30ed2cff1acb3c2b5c59b6b05aab575eb
  claim: Stoke Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: the Company today reported financial results for the first quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1623526/000119312526212020/0001193125-26-212020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.